Evidence map›Paper›PMID 26285951›Full record

Trial reportJournal of diabetes science and technology2015

Glycemic Variability and Its Impact on Quality of Life in Adults With Type 1 Diabetes.

Monika Reddy, Ian F Godsland, Katharine D Barnard, Pau Herrero, Pantelis Georgiou, Hazel Thomson, Desmond G Johnston, Nick S Oliver

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes science and technology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021
    Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Monika ReddyDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK m.reddy@imperial.ac.uk.
Ian F GodslandDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.
Katharine D BarnardHuman Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
Pau HerreroCentre for Bio-Inspired Technology, Department of Electrical and Electronic Engineering, Institute of Biomedical Engineering, Imperial College London, London, UK.
Pantelis GeorgiouCentre for Bio-Inspired Technology, Department of Electrical and Electronic Engineering, Institute of Biomedical Engineering, Imperial College London, London, UK.
Hazel ThomsonDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.
Desmond G JohnstonDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.
Nick S OliverDivision of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.

Funding

Department of Health II-LA-0313-20004Wellcome Trust 100921
6 · The paper itself

Abstract

backgroundThere is evidence suggesting that glycemic variability reduces quality of life (QoL) in people with type 2 diabetes, but this association has not been explored in type 1 diabetes. We aimed to assess whether glycemic variability has an impact on QoL in adults with established type 1 diabetes using multiple daily injections (MDI) of insulin or continuous subcutaneous insulin infusion (CSII).

methodsParticipants wore a blinded continuous glucose monitor for up to 5 days and completed the diabetes quality of life (DQOL) questionnaire. Glycemic variability measures were calculated using the EasyGV version 9.0 software. A correlation analysis was performed to assess whether there was a relationship between glycemic variability and measures of QoL.

resultsIn all, 57 participants with type 1 diabetes (51% male, 65% on CSII, 35% on MDI, mean [SD] age 41 [13] years, duration of diabetes 21 [12] years, HbA1c 63 [12] mmol/mol [7.9% (1.1)], body mass index 25.2 [4.0] kg/m(2)) were included in the analysis. No significant associations between glycemic variability and DQOL total or subscale scores were demonstrated. The glycemic variability was significantly higher for MDI participants compared to CSII participants (P < .05 for all glycemic variability measures), but no significant difference in QoL between the 2 treatment modality groups was observed.

conclusionsTreatment with CSII is associated with lower glycemic variability compared to MDI. Despite this, and contrary to findings in type 2 diabetes, this study did not find an association between glycemic variability and QoL in adults with relatively well-controlled type 1 diabetes, irrespective of whether they are on MDI or CSII.

Indexed as

Quality of LifeAdultBlood GlucoseDiabetes Mellitus, Type 1FemaleGlycemic IndexHumansHypoglycemic AgentsInjections, SubcutaneousInsulinInsulin Infusion SystemsMaleMiddle AgedSurveys and QuestionnairesBlood GlucoseHypoglycemic AgentsInsulincontinuous glucose monitoringglycemic variabilityquality of lifetype 1 diabetes

Identifiers

PMID26285951
PMCPMC4738216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.